PPEF2 Genotype-Guided Iloperidone Selection for Schizophrenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for schizophrenia are highly variable in effectiveness due to individual patient responses, leading to high discontinuation rates and a lack of guidance for selecting the most appropriate medication.
Innovation Solution
Administer antipsychotic agents like iloperidone or mGluR5 agonists to patients based on their PPEF2 genotype, specifically identifying mutations such as R86H or PPEF2:NM_006239:exon3:c.G135A:p.W45X, and tailoring the dose to 12-24 mg/day for optimal treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antipsychotic agents are administered to schizophrenia patients, then psychotic symptoms are treated, but patient response varies highly and discontinuation rate is high
Solution Approach 1:
The patent applies local quality by tailoring treatment to specific patient subgroups based on their PPEF2 genotype. Patients with PPEF2 mutations receive different antipsychotic agents or dosages compared to patients without these mutations, thereby optimizing treatment effectiveness for each genetic subgroup rather than using a uniform approach for all patients.
Solution Approach 2:
The patent utilizes parameter changes by using PPEF2 genotype status as a selecting parameter to determine treatment parameters (drug selection, dosage). This genetic parameter divides the patient population into distinct groups that respond differently to antipsychotic agents, allowing clinicians to adjust treatment parameters based on the patient's genetic profile.
2Reliability
If multiple antipsychotic agents are tried to find the most appropriate medication, then optimal treatment may be achieved, but treatment selection lacks guidance and trial and error is required
Solution Approach 1:
The patent applies preliminary action by performing PPEF2 genotyping before initiating antipsychotic treatment. This preliminary genetic assessment provides advance information about which patients are likely to respond to specific antipsychotic agents, allowing clinicians to select the most appropriate medication from the outset rather than relying on trial and error after treatment has begun.
3Duration of action of stationary object
If antipsychotic treatment is continued to maintain symptom control, then psychotic symptoms are managed, but discontinuation rate remains high due to variable effectiveness
Solution Approach 1:
The patent implements feedback by using PPEF2 genotype information to guide treatment selection and monitoring. This genetic feedback mechanism allows clinicians to identify patients who are likely to respond well to specific antipsychotic agents and maintain long-term treatment, while also identifying patients who may not respond and are at higher risk of discontinuation, allowing for early intervention and treatment adjustment.
Data Source
AI summary
The invention relates generally to improvements in the treatment of psychotic symptoms, and more particularly, to improvements in the identification of an individual or a population of individuals for whom treatment with iloperidone, an iloperidone metabolite, or pharmaceutically-acceptable salts thereof may provide a particular benefit in treating an individual's psychotic symptoms based on the individual's genotype at the PPEF2 locus.